A major evidence review of 17 clinical trials involving more than 20,000 participants found anti-amyloid Alzheimer’s drugs had absent or trivial effects on cognitive decline and dementia. The review also said the drugs likely increase the risk of brain swelling and bleeding.
A review of 17 studies involving 20,342 patients found anti-amyloid Alzheimer’s drugs had “trivial” effects after 18 months and increased the risk of brain swelling and bleeding. A separate PET study suggested ARIA-E may mark brain regions with greater amyloid plaque reduction.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02008357 |
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss |
COMPLETED | PHASE3 |
| NCT01760005 |
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 |
ACTIVE_NOT_RECRUITING | PHASE2/PHASE3 |
